AUTL Autolus Therapeutics ADS

Autolus Therapeutics to Report Third Quarter 2020 Financial Results and Host Conference Call on November 5

Autolus Therapeutics to Report Third Quarter 2020 Financial Results and Host Conference Call on November 5

LONDON, Oct. 30, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its third quarter 2020 financial results and operational highlights before open of U.S. markets on Thursday, November 5, 2020.

Management will host a conference call and webcast at 8:30 am ET/1:30 pm GMT to discuss the company’s financial results and provide a general business update. To listen to the webcast and view the accompanying slide presentation, please go to: .

The call may also be accessed by dialing (866) 679 5407 for U.S. and Canada callers or (409) 217-8320 for international callers. Please reference conference ID 5562455. After the conference call, a replay will be available for one week. To access the replay, please dial (855) 859-2056 for U.S. and Canada callers or (404) 537-3406 for international callers. Please reference conference ID 5562455.

Contact:

Lucinda Crabtree, PhD

Vice President, Investor Relations and Corporate Communications

+44 (0) 7587 372 619

Julia Wilson

+44 (0) 7818 430877

Susan A. Noonan

S.A. Noonan Communications



EN
30/10/2020

Underlying

AUTLAutolus Therapeutics ADS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Autolus Therapeutics ADS

 PRESS RELEASE
Free
AUTL Autolus Therape...

Autolus Therapeutics to Report Second Quarter 2025 Financial Results a...

Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025 LONDON and GAITHERSBURG, Md., July 24, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announces that it will release its second quarter 2025 financial results and operational highlights before open of U.S. markets on Tuesday, August 12, 2025. Management will host a conference call and webcast at 8:30am EDT/13:30pm BS...

July 24, 2025 1 EN
Hilde Van Boxstael ... (+5)
  • Hilde Van Boxstael
  • Livio Luyten
  • Lynn Hautekeete
  • Michiel Declercq
  • Wim Hoste
EXO EXOR N.V.
AUTL AUTOLUS THERAPEUTICS ADS
AKZA AKZO NOBEL N.V.
ECMPA EUROCOMMERCIAL PROPERTIES NV
07/22/25 July 22, 2025 1 EN
Michiel Declercq
  • Michiel Declercq
AUTL Autolus Therape...

Autolus Aucatzyl gains EC approval in r/r adult ALL

Autolus announced that the European Commission (EC) has granted marketing authorization for Aucatzyl (obe-cel, CD19 CAR-T) for the treatment of adults aged 26+ years with r/r B-ALL. Autolus will now evaluate market entry opportunities in the EU, which we expect to take place on a country-by-country basis – the company has previously indicated that the initial focus in the EU will be on Germany. More broadly, the US commercial launch in r/r adult ALL began in early 2025, and the first quarter of ...

AUTL AUTOLUS THERAPEUTICS ADS
07/22/25 July 22, 2025 1 EN
 PRESS RELEASE
Free
AUTL Autolus Therape...

Autolus Therapeutics’ CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel...

Autolus Therapeutics’ CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) Approval is based on FELIX clinical trial of obecabtagene autoleucel (obe-cel) in adult patients with r/r B-ALL, demonstrating high and durable response rates and low toxicityEC approval follows positive CHMP opinion, MHRA conditional marketing authorization and FDA approval LONDON and GAITHERSBURG, Md., July 21, 2025 (GLOBE NEWSWIRE) -- Autolus Therape...

July 21, 2025 1 EN
 PRESS RELEASE
Free
AUTL Autolus Therape...

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing ...

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) LONDON & GAITHERSBURG, Md., July 15, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the compensation committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 360,550 shares of its common stock to 60 employees pursuant to the Company’s 2025 Inducement Plan. The stock opti...

July 15, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch